Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Elisa Giovannetti, Godefridus J Peters, Patrick Pauwels

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.

METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.

RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.

CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

Original languageEnglish
Pages (from-to)425-432
Number of pages8
JournalWorld journal of clinical oncology
Volume7
Issue number6
DOIs
Publication statusPublished - 10 Dec 2016

Cite this

Van Der Steen, Nele ; Deben, Christophe ; Deschoolmeester, Vanessa ; Wouters, An ; Lardon, Filip ; Rolfo, Christian ; Germonpré, Paul ; Giovannetti, Elisa ; Peters, Godefridus J ; Pauwels, Patrick. / Better to be alone than in bad company : The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. In: World journal of clinical oncology. 2016 ; Vol. 7, No. 6. pp. 425-432.
@article{7c2de26fd4794d4a8a65da9d12e19593,
title = "Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer",
abstract = "AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.",
author = "{Van Der Steen}, Nele and Christophe Deben and Vanessa Deschoolmeester and An Wouters and Filip Lardon and Christian Rolfo and Paul Germonpr{\'e} and Elisa Giovannetti and Peters, {Godefridus J} and Patrick Pauwels",
year = "2016",
month = "12",
day = "10",
doi = "10.5306/wjco.v7.i6.425",
language = "English",
volume = "7",
pages = "425--432",
journal = "World journal of clinical oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "6",

}

Better to be alone than in bad company : The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. / Van Der Steen, Nele; Deben, Christophe; Deschoolmeester, Vanessa; Wouters, An; Lardon, Filip; Rolfo, Christian; Germonpré, Paul; Giovannetti, Elisa; Peters, Godefridus J; Pauwels, Patrick.

In: World journal of clinical oncology, Vol. 7, No. 6, 10.12.2016, p. 425-432.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Better to be alone than in bad company

T2 - The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

AU - Van Der Steen, Nele

AU - Deben, Christophe

AU - Deschoolmeester, Vanessa

AU - Wouters, An

AU - Lardon, Filip

AU - Rolfo, Christian

AU - Germonpré, Paul

AU - Giovannetti, Elisa

AU - Peters, Godefridus J

AU - Pauwels, Patrick

PY - 2016/12/10

Y1 - 2016/12/10

N2 - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

AB - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

U2 - 10.5306/wjco.v7.i6.425

DO - 10.5306/wjco.v7.i6.425

M3 - Article

VL - 7

SP - 425

EP - 432

JO - World journal of clinical oncology

JF - World journal of clinical oncology

SN - 2218-4333

IS - 6

ER -